Pfenex Inc (NYSEAMERICAN:PFNX) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 184,290 shares, a decrease of 30.3% from the January 12th total of 264,275 shares. Based on an average daily trading volume, of 125,771 shares, the short-interest ratio is currently 1.5 days. Currently, 0.9% of the shares of the company are sold short.
Pfenex (PFNX) opened at $3.23 on Wednesday. Pfenex has a twelve month low of $2.07 and a twelve month high of $7.93. The stock has a market capitalization of $76.06, a P/E ratio of -1.81 and a beta of 4.04.
Large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its holdings in Pfenex by 112.1% in the second quarter. Dimensional Fund Advisors LP now owns 201,066 shares of the biotechnology company’s stock valued at $806,000 after acquiring an additional 106,257 shares during the period. Sanders Morris Harris LLC lifted its holdings in Pfenex by 33.9% in the third quarter. Sanders Morris Harris LLC now owns 998,151 shares of the biotechnology company’s stock valued at $3,015,000 after acquiring an additional 252,464 shares during the period. Susquehanna International Group LLP acquired a new position in Pfenex in the second quarter valued at approximately $272,000. Goldman Sachs Group Inc. lifted its holdings in Pfenex by 186.0% in the second quarter. Goldman Sachs Group Inc. now owns 160,204 shares of the biotechnology company’s stock valued at $642,000 after acquiring an additional 104,184 shares during the period. Finally, C WorldWide Group Holding A S lifted its holdings in Pfenex by 10.5% in the third quarter. C WorldWide Group Holding A S now owns 271,400 shares of the biotechnology company’s stock valued at $820,000 after acquiring an additional 25,900 shares during the period.
A number of research analysts have issued reports on PFNX shares. JMP Securities decreased their price target on Pfenex from $21.00 to $8.00 and set an “outperform” rating for the company in a report on Friday, November 10th. Zacks Investment Research downgraded Pfenex from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th.
ILLEGAL ACTIVITY NOTICE: “Pfenex Inc (PFNX) Short Interest Down 30.3% in January” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/pfenex-inc-pfnx-short-interest-down-30-3-in-january.html.
Pfenex Company Profile
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.